EPS for Retrophin, Inc. (RTRX) Expected At $-0.53

October 13, 2018 - By Marie Mckinney

Retrophin, Inc. (NASDAQ:RTRX) LogoInvestors sentiment increased to 1.32 in Q2 2018. Its up 0.08, from 1.24 in 2018Q1. It improved, as 10 investors sold Retrophin, Inc. shares while 37 reduced holdings. 25 funds opened positions while 37 raised stakes. 40.01 million shares or 0.71% more from 39.72 million shares in 2018Q1 were reported.
Schwab Charles Inc, California-based fund reported 301,534 shares. Wellington Gp Llp holds 32,401 shares. State Board Of Administration Of Florida Retirement Systems holds 0% or 26,595 shares in its portfolio. Mufg Americas, New York-based fund reported 630 shares. Meeder Asset Inc accumulated 1,122 shares. Lombard Odier Asset Management (Usa) stated it has 252,567 shares. Falcon Point Limited Liability Com invested in 0.74% or 137,376 shares. State Common Retirement Fund stated it has 0% in Retrophin, Inc. (NASDAQ:RTRX). Royal Commercial Bank Of Canada reported 0% in Retrophin, Inc. (NASDAQ:RTRX). Broadfin Cap Ltd stated it has 1.05 million shares. Prudential reported 0.02% stake. Ontario Teachers Pension Plan Board has invested 0.01% in Retrophin, Inc. (NASDAQ:RTRX). Perceptive Advsrs Ltd Company stated it has 3.21M shares or 1.5% of all its holdings. Hbk Investments Lp holds 0.01% or 25,551 shares. Public Employees Retirement Association Of Colorado holds 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX) for 10,796 shares.

Since August 31, 2018, it had 0 insider purchases, and 1 sale for $384,000 activity.

Analysts expect Retrophin, Inc. (NASDAQ:RTRX) to report $-0.53 EPS on November, 6.They anticipate $0.07 EPS change or 15.22 % from last quarter’s $-0.46 EPS. After having $-0.56 EPS previously, Retrophin, Inc.’s analysts see -5.36 % EPS growth. The stock increased 3.63% or $0.9 during the last trading session, reaching $25.7. About 231,498 shares traded. Retrophin, Inc. (NASDAQ:RTRX) has risen 24.42% since October 14, 2017 and is uptrending. It has outperformed by 8.80% the S&P500.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $1.05 billion. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

Another recent and important Retrophin, Inc. (NASDAQ:RTRX) news was published by Globenewswire.com which published an article titled: “Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses” on October 03, 2018.

Retrophin, Inc. (NASDAQ:RTRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>